QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia
Clinical trial NCT06456528 · RECRUITING
Trial details
- NCT number
- NCT06456528
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-10-22
- Primary completion
- 2026-07-01
- Enrollment
- 235
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.